Literature DB >> 20401189

Respiratory syncytial virus immune globulin intravenous.

.   

Abstract

Entities:  

Year:  1998        PMID： 20401189      PMCID： PMC2851255          DOI： 10.1093/pch/3.1.11

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  11 in total

1.  Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  W J Rodriguez; W C Gruber; R C Welliver; J R Groothuis; E A Simoes; H C Meissner; V G Hemming; C B Hall; M L Lepow; A J Rosas; C Robertsen; A A Kramer
Journal:  Pediatrics       Date:  1997-03       Impact factor: 7.124

2.  Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer.

Authors:  C G Prober; E E Wang
Journal:  Pediatrics       Date:  1997-03       Impact factor: 7.124

3.  Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.

Authors:  E A Simoes; J R Groothuis; D A Tristram; K Allessi; M V Lehr; G R Siber; R C Welliver
Journal:  J Pediatr       Date:  1996-08       Impact factor: 4.406

4.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors: 
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

5.  Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1997-04       Impact factor: 7.124

6.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

7.  Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Authors:  H C Meissner; D R Fulton; J R Groothuis; R L Geggel; G R Marx; V G Hemming; T Hougen; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

Authors:  G R Siber; J Leszcynski; V Pena-Cruz; C Ferren-Gardner; R Anderson; V G Hemming; E E Walsh; J Burns; K McIntosh; R Gonin
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

9.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

10.  Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.

Authors:  B Horowitz; M E Wiebe; A Lippin; M H Stryker
Journal:  Transfusion       Date:  1985 Nov-Dec       Impact factor: 3.157
View more
  1 in total

1.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.